The F13B gene encodes the B subunit of the coagulation factor XIII (FXIII). FXIII is the last zymogen to become activated in the blood coagulation cascade. It circulates in blood as a heterotetramer composed of two A- and two B-subunits that are non-covalently associated, designated as A2B2. The A subunits have enzymatic function. The B subunits, which are non-catalytic, serve a carrier function to stabilize the A-subunit in the aqueous environment of human plasma. FXIII is activated by cleavage of the peptide bond between Arg37 and Gly38 of the A-subunit by thrombin followed by subsequent dissociation of the B-subunit from the A-subunit in the presence of calcium ions, yielding the active FXIII enzyme (FXIIIa) composed of 2 activated A subunits. FXIIIa acts as a transglutaminase to catalyze the formation of gamma-glutamyl-epsilon-lysine cross-linking between fibrin molecules, thus rendering the fibrin clot chemically and mechanically more stable as well as resistant to fibrinolysis. Therefore, plasma FXIII plays an important role in wound healing and tissue repair, and it is essential to maintaining pregnancy.
Factor XIII deficiency is an inherited hemorrhagic disease characterized by a lifelong bleeding tendency and abnormal wound healing in affected patients and spontaneous abortion in female patients. This disease had been classified by the presence or absence of antigens into two categories: type I, characterized by the lack of both A- and B-subunits; and type II, characterized by the lack of A-subunit alone. Recently, it is proposed a new classification of factor XIII deficiency at DNA level: XIIIA (former type II deficiency) and XIIIB deficiency (former type I deficiency), and a possible combined deficiency of XIIIA and XIIIB.